Edwards Lifesciences (EW) Competitors

Henry Schein (NASDAQ:HSIC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Do analysts recommend HSIC or EW?

Henry Schein presently has a consensus price target of $75.58, indicating a potential upside of 11.30%. Edwards Lifesciences has a consensus price target of $85.90, indicating a potential upside of 9.85%. Given Henry Schein's higher possible upside, research analysts plainly believe Henry Schein is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	0 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Edwards Lifesciences	1 Sell rating(s)	10 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.65

Which has more volatility & risk, HSIC or EW?

Henry Schein has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Does the media refer more to HSIC or EW?

In the previous week, Henry Schein had 12 more articles in the media than Edwards Lifesciences. MarketBeat recorded 38 mentions for Henry Schein and 26 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.45 beat Henry Schein's score of 0.99 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	18 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	21 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is HSIC or EW more profitable?

Edwards Lifesciences has a net margin of 72.96% compared to Henry Schein's net margin of 3.05%. Edwards Lifesciences' return on equity of 15.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	3.05%	14.36%	5.52%
Edwards Lifesciences	72.96%	15.01%	11.56%

Do insiders and institutionals have more ownership in HSIC or EW?

96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 1.1% of Henry Schein shares are owned by company insiders. Comparatively, 1.3% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has stronger valuation and earnings, HSIC or EW?

Edwards Lifesciences has lower revenue, but higher earnings than Henry Schein. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$12.67B	0.65	$390M	$3.10	21.91
Edwards Lifesciences	$5.44B	8.44	$4.17B	$6.95	11.25

Summary

Edwards Lifesciences beats Henry Schein on 12 of the 17 factors compared between the two stocks.